2022•Cancer MedicineOpen access
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Hira Mian, Richard LeBlanc, Martha Louzada, Esther Masih‐Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Michaël Sébag, Darrell White, Muhammad Aslam, Kevin Song, Tony Reiman, Rami Kotb, Engin Gul, Donna Reece
Open full text 6 citations
Abstract
Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant-ineligible patients with multiple myeloma (MM) that received lenalidomide-dexamethasone as front-line treatment was conducted to understand the impact of lenalidomide dosing. Starting dose modifications were common, 42% of patients started on lenalidomide <25 mg with normal renal function. During treatment course, 35% of patients required further dose reduction. Dose reductions in the first year did not have an impact on progression free survival or overall survival. Further studies need to be conducted to understand the impact of dosing strategies of anti-MM agents in the real world.